This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Discussing the standard of care and/or the potential of Eiger's investigational agent (Peginterferon Lambda) to significantly decrease COVID-19 related hospitalizations or deaths in predominantly vaccinated populations

Ticker(s): EIGR

Who's the expert?

  • Board Certified in Infectious Disease and Internal Medicine
  • Sees patients in inpatient and outpatient setting and at nursing homes and Long term facility. 
  • Chair of Antibiotic Stewardship and Infection Control

Interview Goal
This interview will focus on the potential of Eiger's investigational agent Peginterferon Lambda and the results published in the New England Journal of Medicine from the Phase 3 TOGETHER study regarding Peginterferon Lambda in COVID-19 patients.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.